SCHEDULE: Affinity Asset Advisors Boosts Lexeo Therapeutics Stake
Beneficial Ownership Report
Affinity Asset Advisors and Michael Cho have increased their beneficial ownership in Lexeo Therapeutics, Inc. to 7.1% of common stock.
Summary
- Affinity Asset Advisors, LLC and Michael Cho reported beneficial ownership of 5,217,660 shares of Lexeo Therapeutics, Inc. common stock.
- This represents approximately 7.1% of the outstanding common stock, based on 72,987,327 shares outstanding as of November 3, 2025, plus 867,302 warrant shares.
- The reported amount includes 867,302 shares issuable upon the exercise of warrants.
- As of December 31, 2025, the beneficial ownership was 4,067,302 shares, representing approximately 5.5% of the common stock outstanding.
- The reporting persons now hold sole voting and dispositive power over the 5,217,660 shares.
Sentiment
Score: 7
Explanation: StockSavvy.ai views this as a moderately positive signal, as a significant increase in beneficial ownership by an investment firm suggests confidence in the company's prospects, although it is a routine disclosure and not a direct operational update.
Positives
- Increased stake by Affinity Asset Advisors and Michael Cho, indicating growing confidence in Lexeo Therapeutics, Inc.
- The reporting persons now hold sole voting and dispositive power over their entire 7.1% stake, suggesting consolidated control over their investment.
Future Outlook
NA
Industry Context
StockSavvy.ai notes that an increased stake by an investment adviser like Affinity Asset Advisors in a therapeutics company often signals a positive long-term view on the company's pipeline or market position within the biotechnology or pharmaceutical sector. Such an increase in institutional ownership can be interpreted by the market as a vote of confidence.
Stakeholder Impact
- Shareholders: May view the increased institutional ownership as a positive indicator of confidence in Lexeo Therapeutics, potentially influencing market sentiment.
Key Dates
| Date | Description |
|---|---|
| 2025-11-03 | Date of Issuer's outstanding common stock count (72,987,327 shares) as reported in Form 10-Q. |
| 2025-11-05 | Date Issuer's Form 10-Q was filed with the Securities and Exchange Commission. |
| 2025-12-31 | Previous beneficial ownership reporting date for Affinity Healthcare Fund, LP and Affinity Asset Advisors, LLC (5.5% stake). |
| 2026-01-22 | Date of event requiring the filing of this statement (crossing the 5% threshold or other triggering event for the amendment). |
| 2026-01-29 | Date the Schedule 13G Amendment No. 1 was signed and filed. |
Recommendation
holdThe filing indicates increased institutional confidence in Lexeo Therapeutics through a significant increase in beneficial ownership. While this is a positive signal, a Schedule 13G does not provide sufficient operational or financial details to warrant a 'buy' or 'sell' recommendation. Investors should 'hold' and monitor for further fundamental updates.
Keywords
Lexeo Therapeutics, Affinity Asset Advisors, Michael Cho, Schedule 13G, Beneficial Ownership, Common Stock, Investment Adviser, Biotechnology, Pharmaceuticals
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.